After successfully making our own HER2+/PDL1+ target tumor cells (4T1-Luc-HER2) and third generation anti-HER2 CAR-T cells, we tested the effects of anti-HER2 CAR-T cells on target tumor cells in vitro and in vivo, with or without combination of anti-PD1 antibody. This evidence concerns the gene ERBB2 and neoplasm.